Van ECK Associates Corp Has $21.83 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Van ECK Associates Corp lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 8.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 111,088 shares of the medical research company’s stock after selling 9,751 shares during the period. Van ECK Associates Corp owned 0.06% of IQVIA worth $21,829,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA in the 3rd quarter valued at $27,000. Synergy Asset Management LLC bought a new position in IQVIA in the 4th quarter worth $33,000. Avior Wealth Management LLC raised its holdings in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the period. Assetmark Inc. raised its holdings in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the period. Finally, Concord Wealth Partners bought a new position in IQVIA in the 3rd quarter worth $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on IQV shares. Morgan Stanley lifted their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday. Stephens started coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. Stifel Nicolaus dropped their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, Barclays dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $251.67.

Insider Buying and Selling at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $193.65 on Friday. The stock has a market cap of $35.15 billion, a P/E ratio of 25.82, a PEG ratio of 2.25 and a beta of 1.48. The company’s 50-day simple moving average is $200.59 and its 200 day simple moving average is $218.51. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.